A new review in Genes & Diseases highlights a potential vulnerability in colorectal cancer: the antioxidant defences that help tumour cells survive treatment.
The article examines how adjusting the activity of Nrf2, a regulator of these defences, could help activate cell death pathways and address drug resistance.
Prepared by a team at China Medical University and affiliated hospitals, the review explores a balancing act.
Nrf2 protects healthy intestinal cells from oxidative damage, yet persistent activation in cancer cells can strengthen their defences and reduce sensitivity to chemotherapy.
This dual role makes the pathway a promising but challenging therapeutic target. At the centre of this balance are reactive oxygen species, reactive molecules generated during cellular activity.
Cancer cells operate under heightened oxidative stress and depend on protective systems to keep these molecules within tolerable limits.
Disrupting that balance may push tumour cells toward death, although healthy tissues also require protection.
The review focuses on three interconnected processes: apoptosis, the controlled dismantling of cells; ferroptosis, an iron-dependent form of cell death driven by damage to membrane fats; and autophagy, the recycling machinery that can support survival or contribute to cell death depending on circumstances.
Nrf2 influences these processes by regulating antioxidant production, iron handling and cellular stress responses.
In particular, it can suppress ferroptosis by reinforcing defences against lipid damage. Inhibiting those defences could make some colorectal cancer cells more vulnerable to treatments designed to trigger ferroptosis or increase oxidative stress.
However, the article emphasises that switching Nrf2 off is not a universal solution. Under certain conditions, activating the pathway can also contribute to anticancer effects or protect normal intestinal tissue during treatment.
Effective strategies therefore depend on the biological context, the medicine involved and the cells being targeted.
Potential approaches include combining Nrf2 modulators with chemotherapy, radiotherapy or agents that promote cell death pathways.
Tumour-targeted delivery systems, including nanoparticles, may help concentrate treatment within cancer tissue while limiting effects elsewhere.
The review also highlights the importance of biomarkers, including Nrf2 pathway activity and related genetic features, to identify patients most likely to benefit.
Interactions with immune cells and other supporting cells surrounding tumours add another layer of complexity.
Source: Compuscript Ltd
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.